Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ION363

Oligonucleotide (Antisense oligonucleotide) · developed by IONIS PHARMACEUTICALS

Phase 3 Most advanced trial

IONS Developer

1 Registered trials

What is ION363?

ION363 is an antisense oligonucleotide administered by intrathecal bolus injection. It is being studied in amyotrophic lateral sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (Antisense oligonucleotide)
Therapy area: Neurology
Developer: IONIS PHARMACEUTICALS (IONS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: TND56EA1LE

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04768972	Phase 3	Amyotrophic Lateral Sclerosis	Active not recruiting	IONS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Amyotrophic Lateral Sclerosis

More from IONIS PHARMACEUTICALS

Donidalorsen FDA approved Olezarsen FDA approved Zilganersen FDA approved BIIB094 Phase 1 ION224 Phase 2 ION269 Phase 1 ION337 Phase 1/2 ION356 Phase 1 ION440 Phase 1/2 ION464 Phase 1 ION717 Phase 1/2 ION775 Phase 2

Sources

ClinicalTrials.gov NCT04768972

Updated Oct 3, 2026. Something wrong or missing? Report it on the IONS page.

Follow IONS, the company behind ION363

See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IONS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z